Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Filippo Acconcia"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-21 (2024)
Abstract Breast cancer (BC) is a leading cause of global cancer-related mortality in women, necessitating accurate tumor classification for timely intervention. Molecular and histological factors, including PAM50 classification, estrogen receptor α
Externí odkaz:
https://doaj.org/article/71a103b4fd424bdba5771f8600dcacd8
Publikováno v:
Molecular Oncology, Vol 16, Iss 19, Pp 3568-3584 (2022)
Previously, we found that telaprevir (Tel), the inhibitor of hepatitis C virus NS3/4A serine protease, reduces estrogen receptor α (ERα) content at the transcriptional level without binding to the receptor, prevents ERα transcriptional activity, a
Externí odkaz:
https://doaj.org/article/df0cb0cbff104a4dbfc6b97b3e99803e
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Targeting tumor cell metabolism is a new frontier in cancer management. Thus, metabolic pathway inhibitors could be used as anti-estrogen receptor α (ERα) breast cancer (BC) drugs. Here, the interplay among metabolic enzyme(s), the ERα levels and
Externí odkaz:
https://doaj.org/article/6fbaa480676e46818e890cb7a3b8aa3f
Autor:
Sara Pescatori, Stefano Leone, Manuela Cipolletti, Stefania Bartoloni, Alessandra di Masi, Filippo Acconcia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-27 (2022)
Abstract Background Challenges exist in the clinical treatment of luminal estrogen receptor α (ERα)-positive breast cancers (BCs) both to prevent resistance to endocrine therapy (ET) and to treat ET-resistant metastatic BCs (MBC). Therefore, we eva
Externí odkaz:
https://doaj.org/article/117ca83193164147bed5768e0d70989d
Autor:
Guy Leclercq, Filippo Acconcia
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/eb45451f95a440c385e9512197c044a5
Publikováno v:
Endocrines, Vol 2, Iss 1, Pp 54-64 (2021)
Metastatic estrogen receptor α (ERα)-expressing breast cancer (BC) occurs after prolonged patient treatment with endocrine therapy (ET) (e.g., aromatase inhibitors—AI; 4OH-tamoxifen—4OH-Tam). Often these metastatic BCs express a mutated ERα va
Externí odkaz:
https://doaj.org/article/26511e35ee124590bf1aa107ad6708fd
Autor:
Emiliano Montalesi, Patrizio Cracco, Filippo Acconcia, Marco Fiocchetti, Giovanna Iucci, Chiara Battocchio, Elisabetta Orlandini, Lidia Ciccone, Susanna Nencetti, Maurizio Muzzi, Sandra Moreno, Iole Venditti, Maria Marino
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 2148 (2023)
Breast cancer is the first leading tumor in women in terms of incidence worldwide. Seventy percent of cases are estrogen receptor (ER) α-positive. In these malignancies, 17β-estradiol (E2) via ERα increases the levels of neuroglobin (NGB), a compe
Externí odkaz:
https://doaj.org/article/7a3592d22a4840b7b444ab8c5ddd4004
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 24, p 15809 (2022)
Naringenin (Nar) is one of major citrus flavonoids predominantly found in grapefruit and orange. In vivo studies have demonstrated Nar potential as a normolipidemic agent capable to reduce circulating cholesterol in hypercholesterolemic rabbits, rats
Externí odkaz:
https://doaj.org/article/dace456c31b449c8a8361ea426828f62
Autor:
Filippo Acconcia
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 18, p 10265 (2022)
Breast cancer (BC) is the deadliest neoplastic disease for women worldwide [...]
Externí odkaz:
https://doaj.org/article/879ade5a83c943d0beb005d13a88654f
Autor:
Filippo Acconcia
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11102 (2022)
The molecular classification of breast cancer (BC) dictates pharmacological treatment. Estrogen receptor α (ERα) expressing tumors are treated with 4OH-tamoxifen or fulvestrant, which inhibits the receptor, or with aromatase inhibitors (i.e., anast
Externí odkaz:
https://doaj.org/article/25f91788ce944f24b0f1961f39187101